Form 4: Cytek Biosciences Chief Technology Officer Ming Yan Reports Stock Transactions

Cytek Biosciences' Chief Technology Officer, Ming Yan, reported the acquisition of shares through the vesting of restricted stock units and the subsequent withholding of shares for tax obligations on November 18, 2024.

Summary

• Ming Yan, the Chief Technology Officer of Cytek Biosciences, engaged in multiple transactions involving the company's common stock on November 18, 2024.
• These transactions included the acquisition of shares through the vesting of restricted stock units (RSUs) and the simultaneous disposal of shares to cover tax obligations.
• Specifically, 1,981, 7,363, and 5,525 shares were acquired through RSU vesting, while 483, 1,793, and 1,346 shares were disposed of to satisfy tax withholding requirements.
• The price per share for the tax withholding transactions was $6.03.
• Following these transactions, Ming Yan's direct ownership of Cytek Biosciences common stock stands at 6,018,322 shares, and he holds 73,668 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects the vesting schedule of stock-based compensation for executives.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units is typical for technology companies, with vesting occurring over a four-year period.
• The tax withholding process is standard practice for equity compensation, ensuring compliance with tax regulations.
• Similar filings are regularly made by executives at comparable companies such as Agilent Technologies (A) and Bio-Rad Laboratories (BIO) when they receive or dispose of company stock.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of the standard executive compensation process.

Key Dates

Keywords

Cytek Biosciences, CTKB, insider trading, Form 4, restricted stock units, stock transactions, Ming Yan, Chief Technology Officer, share ownership